2. Search Result
Search Result
Results for "

Synergistic antibacterial activity

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0241
    Dalfopristin
    2 Publications Verification

    RP54476

    		 Antibiotic Bacterial Infection
    Dalfopristin (RP54476) is a semisynthetic sulfone antibiotic. Dalfopristin alone has limited antibacterial activity, but synergistically with Quinupristin it has significant bactericidal activity against many pathogenic Gram-positive cocci .
    Dalfopristin
  • HY-N7368
    Hibifolin

    		Adenosine Deaminase Bacterial Caspase Infection Neurological Disease Inflammation/Immunology Cancer
    Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (Ki = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC50 = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .
    Hibifolin
  • HY-112665
    Virginiamycin Complex

    Streptogramin; Mikamycin; RP 7293

    		 Antibiotic Bacterial Infection
    Virginiamycin Complex (Streptogramin) is an antibiotic containing two streptogramins, virginiamycin M (VM) and virginiamycin S (VS), which are produced by S. virginiae. As a complex, these two antibiotics in Virginiamycin Complex act synergistically. The action of VM is persistent and catalytic, and it can alter the affinity of ribosomes for VS. Virginiamycin Complex irreversibly inhibits protein synthesis in bacteria and has antibacterial activity .
    Virginiamycin Complex
  • HY-Y0850U5
    PVA (Mw 27000, 98-99% hydrolyzed, ~600 polymerization)

    Polyvinyl alcohol (Mw 27000, 98-99% hydrolyzed, ~600 polymerization); Poly(Ethenol) (Mw 27000, 98-99% hydrolyzed, ~600 polymerization)

    		 Biochemical Assay Reagents Fungal Infection
    PVA (Polyvinyl alcohol) (Mw 27000, 98-99% hydrolyzed, ~600 polymerization) is a nonionic ethanol homopolymer with hydrophilicity, water solubility and biodegradability. PVA (Mw 27000, 98-99% hydrolyzed, ~600 polymerization) exhibits biocompatibility, non-toxicity and non-carcinogenicity, as well as antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungal strains. PVA (Mw 27000, 98-99% hydrolyzed, ~600 polymerization) can serve as a solubilizer, stabilizer, mucoadhesive agent and sustained-release agent, and has a synergistic solubilizing effect on voriconazole/sulfobutyl ether β-cyclodextrin complexes. By stabilizing such complexes, PVA (Mw 27000, 98-99% hydrolyzed, ~600 polymerization) forms freeze-thaw hydrogels with high mucoadhesion, sustained drug release and ex vivo corneal permeability. When compounded with hyaluronic acid hydrogels, PVA (Mw 27000, 98-99% hydrolyzed, ~600 polymerization) supports chondrocyte growth in vitro, and also forms complexes with Cu 2+, Co 2+, Ni 2+ and Zn 2+ ions. PVA (Mw 27000, 98-99% hydrolyzed, ~600 polymerization) can be used in studies related to fungal keratitis, bacterial infections and fungal infections .
    PVA (Mw 27000, 98-99% hydrolyzed, ~600 polymerization)
  • HY-P5641
    Pleurocidin
    1 Publications Verification

    		 Bacterial p38 MAPK NF-κB NADH Dehydrogenase Antibiotic Infection Inflammation/Immunology
    Pleurocidin is an Antimicrobial peptide. Pleurocidin is derived from the skin mucosa or intestinal secretions of Pseudopleuronectes americanus. Pleurocidin inhibits the expression of key proteins in the MAPK and NF-κB inflammatory signaling pathways. Pleurocidin alters serum inflammatory and immune cytokine levels, regulates the down-regulation of tight junction proteins, and modulates the intestinal flora. Pleurocidin exerts antibacterial activity by inducing bacterial membrane damage, hydroxyl radical formation, and NADH depletion, and also produces a synergistic effect with Antibiotics. Pleurocidin alleviates DSS-induced ulcerative colitis. Pleurocidin can be used for research on ulcerative colitis, bacterial infections, and bacterial biofilm-related infections .
    Pleurocidin
  • HY-W064918
    NITD-304

    		Bacterial Infection
    NITD-304 is an orally active anti-tuberculosis agent. NITD-304 exerts inhibitory and bactericidal activities gainst Mycobacterium tuberculosis and multidrug-resistant Mycobacterium tuberculosis. NITD-304 inhibits mycobacterial cell wall biosynthesis and demonstrates synergistic or additive growth inhibitory activity with select antibacterial agents. NITD-304 shows low risk of cardiotoxicity and drug-drug interactions, with no inhibition of major cytochrome P-450 enzymes or hERG channel. NITD-304 can be used for the research of tuberculosis and multidrug-resistant tuberculosis .
    NITD-304
  • HY-179415
    DHFR-IN-24

    		Dihydrofolate reductase (DHFR) Bacterial Infection
    DHFR-IN-24, a benzothiazole derivative, is a dihydrofolate reductase (DHFR) inhibitor. DHFR-IN-24 has intrinsic antibacterial activity against both Gram-positive and Gram-negative strains. DHFR-IN-24 synergistically combines DHFR inhibition with photodynamic therapy (PDT) for enhanced antibacterial activity against multidrug-resistant pathogens .
    DHFR-IN-24
  • HY-163191
    NDM-1 inhibitor-5

    		Beta-lactamase Bacterial Infection
    NDM-1 inhibitor-5 (compound 57) is a potent NDM-1 inhibitor, with a Ki of 2.5 μM. NDM-1 inhibitor-5 also shows antibacterial synergistic activity with meropenem (HY-13678) .
    NDM-1 inhibitor-5
  • HY-178111
    AcrB-IN-6

    		Bacterial Infection
    AcrB-IN-6 is an effective AcrB inhibitor. AcrB-IN-6 The compound inhibits the function of bacterial multidrug efflux pumps, thereby significantly enhancing the antibacterial activity of various antibiotics. AcrB-IN-6 achieves 32-fold MIC reductions in wild-type E. coli BW25113. AcrB-IN-6 exhibits excellent synergistic antibacterial effects, low cytotoxicity and hemolytic properties. AcrB-IN-6 can be used for researching anti-resistant bacteria .
    AcrB-IN-6
  • HY-156090
    PK-10

    		Mitochondrial Metabolism Fungal Infection
    PK-10 is a synergistic antibacterial agent of Fluconazole (HY-B0101) and has strong antifungal activity against a variety of Fluconazole-resistant Candida albicans strains. PK-10 combined with Fluconazole can inhibit hyphae formation and induce the accumulation of reactive oxygen species. It further causes damage to mitochondrial membrane potential, reduces intracellular ATP content, and leads to mitochondrial dysfunction .
    PK-10
  • HY-149155
    o-Cymen-5-ol

    		Bacterial Infection
    o-Cymen-5-ol is a broad-spectrum antimicrobial agent with direct antimicrobial activity. o-Cymen-5-ol showed effective minimum inhibitory concentrations (MICs) against a variety of bacteria and fungi, such as Streptococcus mutans and Candida albicans. The combination of o-Cymen-5-ol and zinc showed synergistic effects, enhancing the inhibitory effect against oral pathogens. o-Cymen-5-ol was able to inhibit the glycolysis process and co-enhanced this effect with zinc. o-Cymen-5-ol showed a stronger antibacterial effect in toothpaste than placebo .
    o-Cymen-5-ol
  • HY-179389
    XDS-23

    		Bacterial Glutathione S-transferase Elastase Infection
    XDS-23 is a selective biofilm inhibitor with an IC50 of 1.26 µM against Pseudomonas aeruginosa. XDS-23 exerts a dual inhibitory effect on the LasI/LasR System (las) and Pseudomonas Quinolone Signal System (pqs). XDS-23 suppress the production of key virulence factors including elastase, pyocyanin, and extracellular polysaccharides. XDS-23 exhibits synergistic antibacterial activity and can enhance the efficacy of multiple antibiotics in both in vitro and in vivo models, while maintaining a favorable safety profile. XDS-23 can be employed for research in combating biofilm-mediated drug-resistant P. aeruginosa infections .
    XDS-23
  • HY-173163
    (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium trifluoromethanesulfonate

    		Bacterial Infection
    (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium (trifluoromethanesulfonate) (Compound 4a) is a Gram-negative outer membrane permeabilizer with synergistic antibacterial activity through the blockage on LptA/LptC interaction via targeting Met47 in LptA. (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium (trifluoromethanesulfonate) potentiates pol B against both wild-typed and MDR A. baumannii and E. coli strains. (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium (trifluoromethanesulfonate) can be used as antibiotic adjuvants against MDR Gram-negative bacteria .
    (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium trifluoromethanesulfonate
  • HY-143414
    Metallo-β-lactamase-IN-6

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-6 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.56 μM, 29.50 μM and 5.78 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-6 displays potent synergistic antibacterial activity with Meropenem against engineered Escherichia coli strains and intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL .
    Metallo-β-lactamase-IN-6
  • HY-A0241A
    Dalfopristin mesylate

    RP54476 mesylate

    		 Antibiotic Bacterial Infection
    Dalfopristin (RP54476) mesylate is a semisynthetic sulfone antibiotic. Dalfopristin mesylate alone has limited antibacterial activity, but synergistically with Quinupristin it has significant bactericidal activity against many pathogenic Gram-positive cocci .
    Dalfopristin mesylate
  • HY-161870
    Antibiotic adjuvant 1

    		Antibiotic Infection
    Antibiotic adjuvant 1 (compound 3e) is an antibiotic adjuvant that presents insufficient antibacterial activity (MIC > 128 µg/mL) and potentiate the activity of Cloxacillin (HY-B0466A)(66-fold) with synergistic effect .
    Antibiotic adjuvant 1
  • HY-N14918
    N-(2,6-Diamino-6-hydroxymethylpimelyl)-L-alanine

    		Bacterial Infection
    N-(2,6-Diamino-6-hydroxymethylpimelyl)-L-alanine shows anti-Escherichia coli activity, and is combined with several cell wall synthesis inhibitors such as Fosfomycin, Cycloserine, Penicillin, and Cephalosporin, the combination of sporozoin has obvious synergistic antibacterial effect .
    N-(2,6-Diamino-6-hydroxymethylpimelyl)-L-alanine
  • HY-143415
    Metallo-β-lactamase-IN-7

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-7 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.019 μM, 13.64 μM, 0.38 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-7 potentiate antibacterial activity of Meropenem against the Gram-negative bacterial strains .
    Metallo-β-lactamase-IN-7
  • HY-149333
    BO-1

    		Bacterial Infection
    BO-1 is a benzoate ester with antibacterial activity. BO-1 inhibits multidrug-resistant Staphylococcus aureus, and acts function synergistically with antibiotic, such as Ciprofloxacin (HY-B0356). BO-1 can reverse the resistance of antibiotic-resistant S. aureus strains, and decreases the level of inflammatory factors IL-6 and C-reactive protein in vivo in mice .
    BO-1
  • HY-143236
    DHFR-IN-1

    		Bacterial Fungal Infection
    DHFR-IN-1 (compound 12) is a potent and selective DHFR (dihydrofolate reductase)inhibitor, with an IC50 of 40.71 nM. DHFR-IN-1 exhibits promising antibacterial activity against gram-positive and gram-negative bacteria. DHFR-IN-1 exhibits moderate antifungal activities. DHFR-IN-1 exhibits a high synergistic effect with Levofloxacin (HY-B0330), where the FIC (fractional inhibitory concentration index) value is 0.249 .
    DHFR-IN-1
  • HY-P11040
    Peptide P2.2

    		Bacterial Antibiotic Infection
    Peptide P2.2, a non-ribosomal peptide, is an antimicrobial peptide. Peptide P2.2 has potent antibacterial activity with MIC50s of 4 and 32 μM for V. parahaemolyticus and V. alginolyticus, respectively. Peptide P2.2 increases synergistic antibacterial effects with antibiotics (such as Ofloxacin (HY-B0125) and Linezolid (HY-10394)) with negligible hemolytic activity. Peptide P2.2 disrupts bacterial membranes and increases permeability by modulating proteins involved in the type VI and III secretion systems. Peptide P2.2 can be used for bacterial infections research .
    Peptide P2.2
  • HY-168861
    NDM-1 inhibitor-8

    		Beta-lactamase Bacterial Infection
    NDM-1 inhibitor-8 (Compound 18b) is the covalent inhibitor for new delhi metallo-β-lactamase-1 (NDM-1) with an IC50 of 7.03 μM. NDM-1 inhibitor-8 inhibits the drug resistant strains, exhibits synergistic antibacterial effect with the use of Meropenem (HY-13678). NDM-1 inhibitor-8 exhibits anti-infectious activity in mouse models .
    NDM-1 inhibitor-8
  • HY-112665R
    Virginiamycin Complex (Standard)

    Streptogramin (Standard); Mikamycin (Standard); RP 7293 (Standard)

    		 Reference Standards Antibiotic Bacterial Infection
    Virginiamycin Complex (Standard) (Streptogramin (Standard)) is the analytical standard of Virginiamycin Complex (HY-112665). This product is intended for research and analytical applications. Virginiamycin Complex (Streptogramin) is an antibiotic containing two streptogramins, virginiamycin M (VM) and virginiamycin S (VS), which are produced by S. virginiae. As a complex, these two antibiotics in Virginiamycin Complex act synergistically. The action of VM is persistent and catalytic, and it can alter the affinity of ribosomes for VS. Virginiamycin Complex irreversibly inhibits protein synthesis in bacteria and has antibacterial activity .
    Virginiamycin Complex (Standard)
  • HY-N7368R
    Hibifolin (Standard)

    		Reference Standards Adenosine Deaminase Bacterial Caspase Neurological Disease Inflammation/Immunology Cancer
    Hibifolin (Standard) is the analytical standard of Hibifolin. This product is intended for research and analytical applications. Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (Ki = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC50 = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .
    Hibifolin (Standard)
  • HY-N15435
    Conimine

    		Bacterial Infection
    Conimine is a steroidal alkaloid, antibacterial agent and potentiator. Conimine is isolated from the seeds of Holarrhena antidysenteriaca Wall.ex A.DC. Conimine exhibits intrinsic antibacterial activity against methicillin-sensitive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus. When combined with Penicillin, Conimine shows synergistic antibacterial effects against methicillin-resistant Staphylococcus aureus; when combined with Vancomycin (HY-B0671), it exerts synergistic antibacterial effects against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus .
    Conimine
  • HY-N19219
    Wailupemycin F

    		Antibiotic Endogenous Metabolite Bacterial Infection Cancer
    Wailupemycin F is an Antibiotic and anticancer agent. Wailupemycin F is isolated from the marine-derived Streptomyces maritimus. Wailupemycin F exhibits antibacterial activity against Micrococcus luteus with a MIC of 1.1 μM. Wailupemycin F shows anticancer activity against myeloma. When used in combination with enterocin, Wailupemycin F exerts synergistic antibacterial activity against Micrococcus luteus, doubling its potency. Wailupemycin F can be used in studies related to Micrococcus luteus infection .
    Wailupemycin F
  • HY-182058
    ATM potentiator-1

    		Drug Derivative Bacterial Beta-lactamase Infection
    ATM potentiators-1 is a quercetin derivative that synergistically enhances the antibacterial activity of Aztreonam (ATM, HY-B0129) against metallo-β-lactamase-producing Pseudomonas aeruginosa. ATM potentiators-1 inhibits NDM-1, OXA-10, VIM-2, KPC-2, and OXA-48, suppressing the efflux pump activity of Pseudomonas aeruginosa. When used in combination with CCCP (HY-100941), it exhibits a synergistic inhibitory effect. ATM potentiators-1 is applicable to research related to Pseudomonas aeruginosa infections .
    ATM potentiator-1
  • HY-175731
    FabX-IN-1

    		Bacterial Infection
    FabX-IN-1 (Compound 47) is a selective FabX inhibitor with an IC50 of 0.128  μM. FabX-IN-1 has a narrow-spectrum antibacterial activity against Helicobacter pylori with a MIC of 64 μg/mL, but significantly enhances synergistic inhibitory efficacy combined with membrane permeabilizers, efflux pump inhibitors, and Clarithromycin (HY-17508). FabX-IN-1 can be used for bacterial infections research .
    FabX-IN-1
  • HY-P11468
    wkwkwNGwkwkw-NH2

    		Bacterial Antibiotic Cardiovascular Disease Infection
    wkwkwNGwkwkw-NH2 is a self-assembling β-hairpin antimicrobial peptide. wkwkwNGwkwkw-NH2 self-assembles into nanofibers. wkwkwNGwkwkw-NH2 interacts with LPS on the surface of the bacterial membrane and then disrupts the bacterial outer membrane, inner membrane, and cytoplasmic membrane to exert its antibacterial effects. wkwkwNGwkwkw-NH2 has high antibacterial activity and low hemolytic activity. wkwkwNGwkwkw-NH2 significantly reduces the S. aureus ATCC 25923 load at the skin wound. wkwkwNGwkwkw-NH2 displays synergistic effects when combined with antibiotics. wkwkwNGwkwkw-NH2 facilitates wound healing .
    wkwkwNGwkwkw-NH2
  • HY-183851
    KKL-55

    		Bacterial mRNA Infection
    KKL-55 is a broad-spectrum antibacterial agent that inhibits the trans-translation pathway and the ClpXP protease. KKL-55 suppresses trans-translation of non-stop mRNA, interferes with the binding of EF-Tu to tmRNA, and inhibits the proteolysis of substrates by ClpXP. KKL-55 blocks spore germination of Bacillus anthracis and protects macrophages from damage induced by anthrax toxin. By virtue of its inhibitory effect on ClpXP, KKL-55 synergistically enhances the antibacterial activity of antibiotics against drug-resistant Staphylococcus aureus. KKL-55 can be used in studies related to bacterial infections .
    KKL-55
  • HY-181782
    Gallium hematoporphyrin

    GaHP

    		 Bacterial Reactive Oxygen Species (ROS) Infection
    Gallium hematoporphyrin is a heme analogue and a selective targeting agent against Mycobacteroides abscessus. Gallium hematoporphyrin induces ROS production and inhibits biofilm formation as well as disrupts preformed biofilms in both smooth and rough colony morphotypes of Mycobacteroides abscessus. Gallium hematoporphyrin interferes with heme-dependent metabolic pathways and suppresses the growth of clinical Mycobacteroides abscessus isolatess, with MICs ranging from 0.5 to 1 μg/ml. Gallium hematoporphyrin exhibits synergistic antibacterial activity with Clarithromycin (HY-17508) against Mycobacteroides abscessus. Gallium hematoporphyrin can be used for the research of Mycobacteroides abscessus infection .
    Gallium hematoporphyrin
  • HY-W140346
    Copper(II) pyrithione

    		Environmental Pollutants Beta-lactamase Infection Cancer
    Copper (II) pyrithione is a New Delhi metallo-β-lactamase 1 inhibitor. Copper (II) pyrithione inhibits New Delhi metallo-β-lactamase 1 via transmetallation of its zinc (II) cofactor with copper (II). Copper (II) pyrithione exerts cytotoxic effects on pancreatic cancer cells and osteosarcoma cells. Copper (II) pyrithione exhibits antibacterial activity against Gram-positive bacteria and some Gram-negative bacteria. Copper (II) pyrithione can synergistically enhance the activity of β-lactam antibiotics against β-lactam-resistant bacteria. Copper (II) pyrithione can be used in studies related to pancreatic cancer, osteosarcoma and bacterial infections .
    Copper(II) pyrithione

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: